Sittampalam one page CV-Jan 2016

G. Si&a Si&ampalam, PhD. Na0onal Center for Advancing Transla0onal Sciences (NCATS) Office of the Director/NCATS Na0onal Ins0tutes of Health (NIH) 9800 Medical Center Drive Rockville, MD 20850

Direct Tel : + 301-‐827-‐1070 Mobile: + 317-‐701 7815 E-‐mail: si;[email protected];

Current Role 2011-‐ present •  Senior Advisor to the director on Science & Technology (Christopher

Aus0n MD), Na0onal Center for Advancing Transla0onal Sciences (NCATS/NIH), Rockville, MD, USA.

•  NCATS Council Liaison to the Director, Project Manager for Therapeu0cs for Rare & Neglected Diseases (TRND). Special projects lead on a NCATS collaboraSon with Eli Lily & Co. on phenotypic screening and Automated Organic Synthesis Lab.

•  Special project team member on Pfizer-‐CTI (Center for TherapeuSc InnovaSon) collaboraSon agreement with NCATS in 2014-‐ Discovery and development of biologics.

•  Next generaSon technology development projects at NCATS: 3D BioPrinter collaboraSon with Organovo Holdings, San Diego, CA.

•  Editor-‐in-‐Chief: Assay Guidance Manual, NCBI website hosted by Na9onal Library of Medicine (NIH) website on an NIMH U13 Grant.

•  Editorial Board of Journal of Biomolecular Sciences (2010-‐2013). •  Liaison for NCATS and TRND collaboraSons with mulSple rare disease

foundaSons (Neurofibromatosis, LLS) and PharmaceuScal Companies . Scien0fic Advisory Board: Science Transla9onal Medicine Journal (AAAS), Stemina Biomarker Discovery Inc. Madison WI, USA, Organovo Holdings, San Diego, CA, USA, Science Exchange Inc., San Francisco, CA, USA., UniversiSes of Shady Grove, Montgomery County, MD, USA.

Qualifica0ons & Memberships •  BSc. in Biology & Chemistry, The University of Ceylon, 1969. •  MS. in AnalyScal Chemistry, Bowling Green State University Ohio, USA,

1977. •  PhD. in Chemistry, University of Arizona, USA,1982. •  NIH Post-‐doctoral associate, University of Arizona, USA,1982-‐84. •  Memberships: American AssociaSon for the Advancement of Science; (AAAS), Society for Lab AutomaSon & Screening (SLAS), •  Adjunct Professor, Pharmacology, Toxicology & TherapeuScs, University

of Kansas Medical Center. •  Consultant: InsStute for Advancing Medical InnovaSons, The University

of Kansas Cancer Center and mulSple ScienSfic Advisory Boards (SAB)

Past Scien0fic & Management Experience

Si&ampalam: Professional Profile Na0onal Center for Advancing Transla0onal Sciences (NCATS/NIH)

January 2016

Scien0fic Contribu0ons & Exper0se

•  1984-‐2007: Senior scienSfic and management posiSons posiSons at Lilly Research Laboratories, Eli Lilly & Co, USA: Bio Product development. New technology development for recombinant protein product development, 2001-‐2007: Op0miza0on Laboratory, Head: Eli Lilly & Company, USA (US$11 mil/year budget). HTS, drug discovery, Lead OpSmizaSon & development. ParScipated in mulSple management commi;ees on regulatory submissions, product and quality reviews, career and personal development & diversity commi;ees. stem cell-‐based screening strategies for drug discovery. •  1995-‐present: Founding member of the Society of Biomolecular Sciences (SBS) (1994-‐95);Board member SBS: 1997-‐2000; President of SBS 2003-‐04. •  2001-‐ present: Na0onal Ins0tutes of Health (NIH) USA, Research Grant review panels. Stem cell research special review panel member with the California InsStute of RegeneraSve medicine, and the Maryland Stem cell Research Fund. •  2007-‐2011: Professor, Pharmacology, Toxicology and TherapeuScs, University of Kansas (KU) Medical Center. Teaching & managing external collaboraSons for IAMI. •  2007-‐2011: Ins0tute for Advancing Medical Innova0ons( IAMI) and KU High Throughput Screening Center and the NIH Chemical Genomics Center(NIH), Wake Forest InsStute of RegeneraSve Medicine, the NaSonal Leukemia & Lymphoma Society, USA, and the Stowers InsStute for Medical Research, Kansas City, KS, USA. •  2007-‐2011: Director of a Tumor Tissue Engineering facility. University of Kansas Technology CommercializaSon advisory panel on intellectual property management. Member, Leadership Council, The University of Kansas Cancer Center. Management of High Throughput Screening (HTS) Facility at Lawrence campus (US$5 mil state-‐of-‐the-‐art facility). •  2011-‐: NCATS R&D Best Prac0ces & Collabora0ons. NCATS Consultant to Kyushu University, Fukuoka Japan: Development of TranslaSonal Sciences and Rare & Neglected Diseases Program.

•  Over 250 invited scienSfic presentaSons and seminars in NaSonal & InternaSonal meeSngs. •  Organized mulSple scienSfic symposia in naSonal & internaSonal meeSngs •  40+ ScienSfic papers in peer-‐reviewed naSonal & InternaSonal journals. •  Contributed to the therapeu0c development of HumulinTM (human insulin), HumalogTM (Lys-‐Pro Insulin), HumatropeTM ( Human Growth Hormone), XigrisTM (acSvated Protein C), GemcitabineTM at Eli Lilly & Co. •  Recognized scienSfic leader in drug discovery, lead opSmizaSon, HTS assays

and technology development. •  Current interests are in PharmaceuScal R&D policy and best pracSces, rare

disease biology, stem cell-‐based high throughput screening, tumor Sssue engineering and regeneraSve pharmacology, 3D BioprinSng technology.

Na0onal Ins0tutes of Health (NIH), USA

Sittampalam one page CV-Jan 2016

Documents

Transcript of Sittampalam one page CV-Jan 2016